INNOVIVA INC (INVA)
Health Care · NASDAQ
A diversified biopharmaceutical company combining respiratory royalties from GSK blockbusters (BREO, ANORO) with a growing critical care and infectious disease platform (GIAPREZA, XACDURO, ZEVTERA, NUZOLVENCE).
What INNOVIVA INC does
Innoviva is a biopharmaceutical company with three main business segments: a respiratory royalty portfolio from GSK (receiving 5–15% royalties on BREO ELLIPTA and ANORO ELLIPTA), a wholly-owned critical care and infectious disease platform (IST) with five marketed hospital-focused products, and strategic healthcare investments including a significant stake in Armata Pharmaceuticals. The company generates revenue from royalties, net product sales from its own therapeutic products, and license agreements.
Themes: ["respiratory royalties / COPD / asthma"]
Fundamentals
- Price$22.20 as of 2026-07-09 close
- Market cap$1.6B as of 2026-07-10
- 1-year return+15.8% as of 2026-07-09 close
- P/E3.24 as of 2026-07-10
- Net margin+119.9% as of 2026-07-10
- Gross margin+73.7% as of 2026-07-10
- ROE+47.6% as of 2026-07-10
- Debt / equity0.19 as of 2026-07-10
- Revenue growth (YoY)+13.8% as of 2026-07-10
- Revenue CAGR (3y)+7.5% SEC XBRL
- Beta0.34 as of 2026-07-10
Key risks (from latest filing)
["Dependence on GSK royalties (BREO and ANORO) for significant portion of revenue; exposure to COPD/asthma market competition and pricing pressure."]
Competitors & peers
- GlaxoSmithKline (GSK) — COPD/asthma (Advair)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.